INSY Insys Therapeutics Inc.

8.81
-0.06  -1%
Previous Close 8.87
Open 8.86
Price To book 2.41
Market Cap 640457460
Shares 72,696,647
Volume 382,980
Short Ratio 17.67
Av. Daily Volume 532,144

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 171009729
  2. 8-K - Current report 171002807
  3. 8-K - Current report 17972947
  4. 8-K - Current report 17847390
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 17825856

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved January 5, 2012.
SUBSYS
Cancer pain
Phase 2 initiated August 2016
Pharmaceutical Cannabidiol (CBD)
Cocaine dependence
Announced approval July 5, 2016.
Dronabinol Oral Solution
AIDS-related anorexia
Phase 2 enrollment initiated February 2016
Pharmaceutical Cannabidiol (CBD)
Infantile spasms (IS)
Phase 3 planned.
Cannabidiol
Epilepsy
Phase 3 data met primary endpoints - August 2016
Buprenorphine
Moderate to severe postoperative pain after bunionectomy
Dose ranging trial to be initiated 1H 2015, with Phase 3 to be initiated 2H 2015. Data due 2016.
Subsys
Acute post-operative pain

Latest News

  1. INSYS Therapeutics to Present at Cantor Fitzgerald Global Healthcare Conference
  2. INSYS Therapeutics Hires First Corporate Communications Leader and New Investor Relations Agency
  3. Our 5 Top Picks For A Booming Marijuana Market
  4. Montel Williams' Battle With Multiple Sclerosis And The Miracle Of Medical Marijuana
  5. Of the 14 Largest Marijuana Stocks, Only These 2 Are Down Over the Past Year
  6. ETFs with exposure to INSYS Therapeutics, Inc. : September 14, 2017
  7. Company under fire for opioid marketing files patent suit
  8. INSYS Therapeutics, Inc. :INSY-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017
  9. 3 PR Scandals Creating Intriguing Buying Opportunities
  10. Have Investors Already Priced In INSYS Therapeutics Inc’s (INSY) Growth?
  11. [$$] Opioid Maker Bent Rules to Get Drug to Patients, Senate Report Says
  12. U.S. senator reveals results of opioid inquiry into Insys
  13. Why This Marijuana Stock Crashed 18.5% in August
  14. 5 of the Most Hated Biotech Stocks on the Market: Are They Buys?
  15. Insys Addresses Arizona Attorney General Complaint
  16. [$$] Arizona Accuses Insys of Fraudulently Marketing Fentanyl Painkiller
  17. Arizona accuses drugmaker Insys of fraudulent opioid marketing
  18. AG's office files lawsuit against opioid manufacturer Insys Therapeutics
  19. Corporate News Blog - Insys Therapeutics Releases Statement on Illinois Settlement; Provides Data against the Opioid-Induced Calamity in the US
  20. Insys Addresses Questions Raised by Illinois Settlement

SEC Filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 171009729
  2. 8-K - Current report 171002807
  3. 8-K - Current report 17972947
  4. 8-K - Current report 17847390
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 17825856
  6. 8-K - Current report 17824791
  7. 8-K - Current report 17823045
  8. DEF 14A - Other definitive proxy statements 17765754
  9. 8-K - Current report 17763409
  10. 10-Q/A [Amend] - Quarterly report [Sections 13 or 15(d)] 17750839